NASDAQ:CABA Cabaletta Bio (CABA) Stock Forecast, Price & News $15.22 +0.02 (+0.13%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$15.05▼$15.4850-Day Range$11.84▼$18.6552-Week Range$0.63▼$19.34Volume596,887 shsAverage Volume1.05 million shsMarket Capitalization$605.91 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cabaletta Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside38.0% Upside$21.00 Price TargetShort InterestBearish7.89% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.29Based on 3 Articles This WeekInsider TradingSelling Shares$492,910 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.51) to ($1.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector528th out of 972 stocksBiological Products, Except Diagnostic Industry77th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, Cabaletta Bio has a forecasted upside of 38.0% from its current price of $15.22.Amount of Analyst CoverageCabaletta Bio has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.89% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 3.68%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CABA. Previous Next 4.1 News and Social Media Coverage News SentimentCabaletta Bio has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cabaletta Bio this week, compared to 2 articles on an average week.Search Interest45 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows5 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $492,910.00 in company stock.Percentage Held by Insiders12.33% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cabaletta Bio are expected to grow in the coming year, from ($1.51) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 4.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cabaletta Bio (NASDAQ:CABA) StockCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More CABA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CABA Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comCabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Rating of "Buy" from AnalystsSeptember 25, 2023 | finance.yahoo.comWhat Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'October 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 23, 2023 | markets.businessinsider.comPromising Safety and Efficacy Data for Cabaletta Bio’s CD19 CAR-T Therapy Bolsters Buy RecommendationSeptember 19, 2023 | msn.comCabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?September 8, 2023 | msn.comCabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be SustainableSeptember 5, 2023 | markets.businessinsider.comAnalyst Ratings for Cabaletta BioSeptember 5, 2023 | cnbc.comThis little-known biotech stock has 'blockbuster potential,' says CitiOctober 1, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 5, 2023 | markets.businessinsider.comCabaletta Bio (CABA) Receives a Buy from CitiAugust 31, 2023 | finance.yahoo.comWall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to TradeAugust 30, 2023 | finance.yahoo.comCabaletta Bio to Participate in Multiple Upcoming Investor Conferences in SeptemberAugust 25, 2023 | finance.yahoo.comLab Notes: Wistar, Coriell researchers identify potential target for gastric cancers treatmentAugust 23, 2023 | finance.yahoo.comRecent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's WhyAugust 22, 2023 | lse.co.ukOxford BioMedica expands licence deal with Cabaletta BioAugust 21, 2023 | finance.yahoo.comWe Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business GrowthAugust 15, 2023 | finance.yahoo.comDoes Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect?August 14, 2023 | msn.comGuggenheim Reiterates Cabaletta Bio (CABA) Buy RecommendationAugust 12, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Cabaletta Bio (CABA)August 12, 2023 | msn.comHC Wainwright & Co. Maintains Cabaletta Bio (CABA) Buy RecommendationAugust 12, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Cabaletta Bio: Here's What You Need To KnowAugust 10, 2023 | finance.yahoo.comCabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 2, 2023 | msn.comCabaletta Bio (CABA) Price Target Increased by 20.00% to 17.34August 1, 2023 | msn.comTop Growth Stocks for August 2023July 24, 2023 | finance.yahoo.comCabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of DirectorsJuly 19, 2023 | msn.comGuggenheim starts Cabaletta at buy, citing CAR-T therapy CABA-201July 19, 2023 | nasdaq.comGuggenheim Initiates Coverage of Cabaletta Bio (CABA) with Buy RecommendationSee More Headlines Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address CABA Company Calendar Last Earnings8/10/2023Today10/01/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CABA CUSIPN/A CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees77Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.00 High Stock Price Forecast$39.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+38.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.38% Return on Assets-46.27% Debt Debt-to-Equity RatioN/A Current Ratio20.93 Quick Ratio20.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.60 per share Price / Book4.23Miscellaneous Outstanding Shares39,810,000Free Float34,897,000Market Cap$605.91 million OptionableNot Optionable Beta2.55 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Steven A. Nichtberger M.D. (Age 62)Co-Founder, Chairman, CEO & Pres Comp: $970.6kDr. Gwendolyn K. Binder Ph.D. (Age 48)Pres of Science & Technology Comp: $692.99kDr. David J. Chang FACR (Age 60)M.D., M.P.H., Chief Medical Officer Comp: $676.74kDr. Michael C. Milone M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardDr. Aimee Payne M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardMr. Anup Marda M.B.A. (Age 46)Chief Financial Officer Dr. Samik Basu M.D.Chief Scientific OfficerMr. Michael Gerard J.D. (Age 43)Gen. Counsel & Sec. Ms. Heather Harte-Hall M.Sc.Chief Compliance OfficerMs. Martha O'ConnorChief HR OfficerMore ExecutivesKey CompetitorsEditas MedicineNASDAQ:EDITVectivBioNASDAQ:VECTExscientiaNASDAQ:EXAIAllogene TherapeuticsNASDAQ:ALLOAnavex Life SciencesNASDAQ:AVXLView All CompetitorsInsiders & InstitutionsBarclays PLCSold 62,102 shares on 9/21/2023Ownership: 0.013%Gwendolyn BinderSold 11,000 sharesTotal: $193,270.00 ($17.57/share)Perceptive Advisors LLCBought 820,223 shares on 8/24/2023Ownership: 3.881%Affinity Asset Advisors LLCBought 125,000 shares on 8/21/2023Ownership: 0.314%Gwendolyn BinderSold 11,000 sharesTotal: $147,620.00 ($13.42/share)View All Insider TransactionsView All Institutional Transactions CABA Stock - Frequently Asked Questions Should I buy or sell Cabaletta Bio stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CABA shares. View CABA analyst ratings or view top-rated stocks. What is Cabaletta Bio's stock price forecast for 2023? 7 Wall Street research analysts have issued twelve-month target prices for Cabaletta Bio's stock. Their CABA share price forecasts range from $10.00 to $39.00. On average, they predict the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 38.0% from the stock's current price. View analysts price targets for CABA or view top-rated stocks among Wall Street analysts. How have CABA shares performed in 2023? Cabaletta Bio's stock was trading at $9.25 on January 1st, 2023. Since then, CABA stock has increased by 64.5% and is now trading at $15.22. View the best growth stocks for 2023 here. When is Cabaletta Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our CABA earnings forecast. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) released its earnings results on Thursday, August, 10th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.10. What ETFs hold Cabaletta Bio's stock? ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE). When did Cabaletta Bio IPO? (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO. What is Cabaletta Bio's stock symbol? Cabaletta Bio trades on the NASDAQ under the ticker symbol "CABA." How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cabaletta Bio's stock price today? One share of CABA stock can currently be purchased for approximately $15.22. How much money does Cabaletta Bio make? Cabaletta Bio (NASDAQ:CABA) has a market capitalization of $605.91 million. The company earns $-52,970,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. How can I contact Cabaletta Bio? Cabaletta Bio's mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The official website for the company is www.cabalettabio.com. The company can be reached via phone at 267-759-3100 or via email at investors@cabalettabio.com. This page (NASDAQ:CABA) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.